CN Mobile Logo

Search form


Bryant Furlow

Bryant Furlow

Posts by Author

Atezolizumab treatment beyond progression might benefit patients with advanced non–small-cell lung cancer, according to the first report from the randomized phase III OAK trial.

Lorlatinib exhibits durable responses in patients with ALK-positive non–small-cell lung cancer and robust intracranial activity in those with brain metastases.

Liver toxicity precludes development of pembrolizumab plus pazopanib immunotherapy for patients with advanced renal cell carcinoma.

Despite high rates of toxicity, a first-line tyrosine kinase inhibitor/immunotherapy combination exhibits promising antitumor activity in metastatic renal cell carcinoma.

Plasma levels of HGF, BAP1 and PBRM1 gene mutation status, and angiogenesis gene expression are promising predictive biomarkers for survival in RCC patients.

The investigational third-generation nonsteroidal oral selective estrogen receptor degrader RAD1901 was associated with a 23% objective response rate among 40 heavily pretreated women with estrogen receptor (ER)-positive, HER2-negative breast cancer.

Adding ipatasertib to first-line paclitaxel modestly improved progression-free survival in women with triple-negative breast cancer.

Despite previously reported progression-free survival improvements with cediranib, results from the ICON6 trial failed to show a statistically significant improvement in overall survival.

Individualizing first-line sunitinib was associated with improved response and survival times among patients with metastatic renal cell carcinoma.

Adjuvant radiotherapy for diffuse large B-cell lymphoma is unnecessary for elderly patients who have PET-negative bulky disease following immunochemotherapy.


By clicking Accept, you agree to become a member of the UBM Medica Community.